ロード中...
Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99
BACKGROUND: The HER2 extracellular domain shed in blood (HER2(ECD)) is reported to rise and fall in parallel with HER2+ breast cancer behavior. In this study, we evaluated the clinical relevance of plasma HER2(ECD) values in patients with metastatic breast cancer treated in the SAKK22/99 trial compa...
保存先:
| 出版年: | BMC Cancer |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7014942/ https://ncbi.nlm.nih.gov/pubmed/32046665 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-6594-0 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|